Anda di halaman 1dari 33
Final report
Final report
S W I T Z E R L A N D C H - 4 0
S W I T Z E R L A N D
C H - 4 0 0 2
B A S E L
1 2 / 2 0 / 2 0 1 2
SUBMITTED TO
NO V A R T I S
SIR ABDUL KHALIQ
ANUM ZAHRA 134
4 1 6 1 3 2 4 1 1 1 1
4 1 6 1 3 2 4 8 0 0 1

1

ABSTRACT

Medicine is incredibly important to us we need medicine because that it helps to maintain or restore our health prevent of disease, injury and other damage to our body or mind.

Medicine can cure illness, boost immunities, provide extra nutrients and vitamins that the body can't produce or consume on a daily diet and Novartis is one of the best pharmaceutical company which have its business in 140 countries and this report contains mission , vision ,offices detail , check list for cooperate strategies , flow of productivity , detail of products , customer contact matrix , product matrix , culture of organization , competitive advantage , training methods , success stories and swot analysis of the Novartis pharmaceutical company .Novartis is the only pharmaceuticals producer that has considerable competitive advantages in key industry success factors such as R&D ,competent employees ,financial strengths ,marketing & sales & organizational efficiency.

2

TABLE OF CONTENTS

Introduction

  • Background of Novartis…………………………………………………… 3 ..

  • Purpose …………………………………………………………………… 4 ...

  • Scope……………………………………………………………………… 4 ...

  • Method used…………………………………………………………………4

  • History……………………………………………………………………….5

  • Mission & vision…………………………………………………………….6

  • Offices of Novartis in Pakistan……………………………………………6-7

  • List of competitors………………………………………………………… 8 ...

Body

  • Fishbone diagram ……………………………………………………………9

  • Histrogram………………………………………………………………10-11

  • Checklist for the cooperate strategies………………………………………12

  • Products…………………………………………………………………… 13 ..

  • Products in Pakistan……………………………………………………… 14 ...

  • Customer contact matrix…………………………………………………….15

  • Product matrix……………………………………………………………….16

  • Productivity flow chart………………………………………………………17

  • Culture of organization………………………………………………………18

  • Competitive advantages…………………………………………………… 19 ...

  • Training undergone ………………………………………………………….20

  • Success stories……………………………………………………………21-27

  • Failures/threats……………………………………………………………….28

Conclusion…………………………………………………………… 29 ... Recommendations…………………………………………………… 30 ..

Bibliography……………………………………………………………31

Glossary……………………………………………………………..31-32

3

Introduction of Novartis

Novartis have diversified portfolios ALCON (EYE CARE) ,SANDOZ(GENERICS) , SELF CARE PRODUCTS , VACCINES & DIANOSTICS AND ANIMAL HEALTH CARE is a world leader in the research, development, production and marketing of self-care products. Products are designed for in-home treatment of medical conditions and ailments to help improve people’s ability to live the healthy lives they want for themselves and their families. NOVARTIS have a robust portfolio of cough, cold, respiratory disease treatments, digestive health solutions and pain management medication as well as skin care products, smoking-cessation therapies and mineral supplements.

BACK GROUND

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010 and employs 96717 people.

It is engaged in the research development, manufacture ,marketing of branded drugs generic pharmaceutical products ,preventive vaccines, Diagnostic tools & consumer health products. The company operates in more than 140 countries across the globe.

Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren),carbamazepine (Tegretol), valsartan (Diovan), imatinibmesylate and (Gleevec / Glivec). Additional agents include cyclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.

4

PURPOSE

The purpose of report is to get information about Novartis pharmaceutical company which is working in 140 countries.

The report covers the company’s structure, operation, SWOT analysis, product and

service offerings, sales, and corporate stretegies, providing a 360° view of the company

Scope This report contains following information

  • Provides detailed information on Novartis AG required for business and competitor intelligence needs

  • Contains a study of the major internal and external factors affecting Novartis AG in the form of a SWOT analysis

  • Offers an in-depth view of the business model of Novartis AG including a breakdown and examination of key business segments

  • Contains five-year financial information and charts of Novartis AG.

  • Provides intelligence on Novartis AG’s mergers and acquisitions , strategic partnerships and alliances.

  • Captures the latest news about Novartis AG, such as business expansion, restructuring, and contract wins Highlights:

This report includes Novartis AG's business description, segment overview, company history, products and services, SWOT analysis, 5-year sales and management , key executives and biographies, key

METHOD USED

Background research

Like an information scan, background research can involve a number of things:

  • - Online research;

  • - Speaking to experts who give an overview of topic;

  • - Reading various literature

5

History

Novartis pharmaceutical is established in 1996.The history of Novartis traces back to three companies

  • Geigy Pharmaceutical

  • Ciba pharmaceutical

  • Sandoz pharmaceutical

Giegy whose origin goes back to the middle of the 18thcentury.

CIBA founded around1859and Sandoz established in 1886In1970 CIBA and Giegy merged .the newly created CIBA-Geigy ltd and Sandoz continued to follow separate path for two and half decades In1996 Sandoz and CIBA- Geigy joined to form Novartis pharmaceutical.

6

NOVARTIS PHARMA PAKISTAN Head Office

Novartis International AG

CH-4002 Basel Switzerland Tel: +41 61 324 11 11Fax: +41 61 324 80 01

Head office in Pakistan Novartis Pharma (Pakistan) LTD.

15

West Wharf Road, Karachi 74000, Sindh, Pakistan

Phone:

9221-2313389 / 2316286 / 2313387 / 2313390

Fax:

 

9221-2310241

Mission:

We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.

 

Vision:

We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequate those who invest ideas and work in our company.

 

Sector Head

Farhan Baider Malik

15

West Wharf Road, Karachi 74000, Sindh, Pakistan

Phone:

9221-2313389 / 2316286 / 2313387 / 2313390 Fax: 9221-2310241 Managers Khalid Ashraf (National Sales Manager) Moiz Haider(Brand Manager)

7

Zubair Ahmed(Training Manager) Ali Imran (Human Resource Manager) Moin Khan (Factory head)

Regional Sales Managers Tuyyab Nazir Lahore Mujeeb Alam Multan M Shakeel Karachi Arshad Iqbal

Islamabad

Zonal Sales Managers Lahore

Muhammad Zeeshan Altaf M. Sohail Aslam

Faisalabad

M. Ejaz Qamer Shahzad Ali

Islamabad

Naveed Basheer Ikram Ulah Khan M.Usman

Multan

Shahzad Jamil Ghazanfar Aziz Ghauri Qamar Zaman

Gujranwala

AbaidurRehman

Sukhar

Imtiaz Soomro Abdul Hameed

Karachi

Faizan Ur Rehman Syed Ather Hussain Asif Ali Khan

Hyderabad Jawaid Jabbar Syed Shoaib Hussain Naveed Farooque

8

LIST OF COMPETITORS

8 LIST OF COMPETITORS

9

FISH BONE DIAGRAM REGARDING ISSUES OF PRODUCTIVITY

Work force INOVATION Bonuses & benefits R&d prog Technolog Pipeline industry Continuous training PRODUCTIVE EFFICIENCY Proved
Work force
INOVATION
Bonuses & benefits
R&d prog
Technolog
Pipeline industry
Continuous training
PRODUCTIVE
EFFICIENCY
Proved by FDA
R&D prog
Pipeline industry
Harmless
Diagnostic tools
drugs
& capital
DIVERSIFICATION
Quality

10

GRAPH OF PRODUCTIVITY

   

SALES

YEARS

  • 7567800 2006

 
  • 7266120 2007

 
  • 7459640 2008

 
  • 7735281 2009

 
  • 6910000 2010

 
  • 7248552 2011

 
  • 7148352 2012

 
SALES YEARS 7735281 7568600 7459640 7266120 7248552 7148352 6910000 2006 2007 2008 2009 2010 2011 2012
SALES
YEARS
7735281
7568600
7459640
7266120
7248552
7148352
6910000
2006
2007 2008
2009 2010
2011 2012
1
2
3
4
5
6
7

11

UNITS PRODUCED CO DIVON

YEARS

  • 2000 2007

  • 1800 2008

  • 1850 2009

  • 1900 2010

  • 2050 2011

  • 2100 2012

1800 1 2 5 3 7 4 6 1650 1700 1750 UNITS PRODUCED CO 1850 1900
1800
1
2
5
3
7
4
6
1650
1700
1750
UNITS PRODUCED CO
1850
1900
1950
2000
2050
2100
2150
YEARS
DIVON

12

CHECK LIST OF CORPORATE STRATEGIE

  • R &D PROGRAM IN INDUSTRY

  • DIVERSIFIED HEALTH CARE PORTFOLIO

  • GROUP WIDE PRODUCTIVITY INITIATIVES

  • BROADER PORTFOLIOS TO MEED DEMAND

  • FOCUSED SOLELY ON HEALTHCARE

  • INNOVATION

  • GREATER EMPHASIZE ON PRODUCTIVITY

  • STRONG CASH FLOW RETURNS

  • REINVESTMENT FOR FUTURE GROWTH

  • SHARE HOLDER RETURNS

  • REINVEST INTO INNOVATIVE PRODUCTS

  • GAIN GREATER OPERATING LEVERAGE

  • CONTINUED INVESTMENT IN R&D

  • improve efficiency in manufacturing, sales, marketing and procurement

  • Giving bonuses to employees on annual basis

  • Every step is taken according to the planning

14

PRODUCTS AVAILABLE IN PAKISTAN

TAB MEPRESSOR 100 MG TAB MAPRESSOR 200 MG TAB VOLTRAL 50 MG TAB VOLTRAL 100 MG TAB TEGRAL 200 MG TAB TERNALINE 2 MG ,4 MG TAB ANNUVA 50 ,100 MG TAB HYDERGINE 4.5 MG ,1.5 MG HYDERGINE SYRUP CAC 1000 INJ SANTOCINON INJ METHERGIN DIOVAN 160 MG , 320 MG CO DIOVAN 160/25 MG GALVUS 50 MG GALVUS MET 50/500MG GALVUS MET 50/1000MG

15

Customer contact matrix

less customer contact & customization

15 Customer contact matrix less customer contact & customization PROCESS High interact Some interact Low interact

PROCESS

High interact

Some interact

Low interact

CHARACTERISTICS

Flexible flow

Front office e.g medical stores

   

Flexible flow

 

Hybrid officee.g

 

Medium flexibility

distributers

Lowest complexibility

   

Back office

e.g company

There is less process divergence & more line flows vertically

16

PRODUCT MATRIX

less customization & higher volume less divergence & more line flow vertically

16 PRODUCT MATRIX less customization & higher volume less divergence & more line flow vertically Process
16 PRODUCT MATRIX less customization & higher volume less divergence & more line flow vertically Process

Process

Low volume

Multiple products with

Few major

High volume

characteristics

products

low to oderate level

products

high

standardization

Customized process

Job process

     

with flexible and

e.g DIVON

unique task

For Heart

failures

Disconnected line flows moderately

 

Batch process 1.smalle.g ANNOVA

   

repetitive work

2.large

e.g MEPRESSER General blood pressure

Connected line

   

Line process

 

highly repetitive

e.g ELGIN

work

multivitamin vitamin B 12

Continuous flow

     

Continuous flow

process

e.g VOLTRAL

pain killer

17

PRODUCTIVITY FLOW CHART

CO-DIVON
CO-DIVON
FORMUL 160/25
FORMUL 160/25

PROPER MIXING OF valsartan & hydrochlorothiazide

Analyse the problem
Analyse
the
problem

Stop the production

Checking the quality whether no meet the yes
Checking
the quality
whether
no
meet the
yes

Dispatch the production

18

Culture of the organization

Culture and values

  • At Novartis, our performance-oriented culture and responsible approach are the foundations of our success. We recognize that our business depends on the

  • creativity,

  • dedication

  • performance of our associates. We encourage associates to focus on achievement through

  • collaboration and innovation.

  • A pipeline of innovative medicines brought to life by

  • diverse

  • talented

  • performance driven people. All of which makes us one of the most rewarding employers in our field.

Diversity and inclusion

Novartis is committed to equality of

  • opportunity

  • fairness

  • work

  • lifestyle

  • mutual respect

  • dignity at work for all associates.

  • Novartis values differences including disability, sexual orientation, race, ethnicity, age, thinking styles, gender and religion.

Inclusion establishes and reinforces behavioural standards that foster a collaborative culture and work environment, which will enable individuals and groups to contribute

to their fullest potential. Diversity and Inclusion adds value for our company, patients customers associates shareholders suppliers & the communities in which we live and work

19

COMPETITIVE ADVANTAGES IN PAKISTAN & INTERNATIONALY

 

STRENGTHS

Strengths

Market leader Strong cns image of Novartis Strong brand image heritage valuation High acceptance of carbamazepine a anti epileptic FDA approved Effective in multiple indications First line , first choice therapy

More COMPETITIVE ADVANTAGES

  • VACCINES BUSINESS SHOWCASING

  • LEADING PIPELINE INDUSTRY

  • INNOVATIVE MEDICINES

  • 17 VACCINES CANDIDATES IN VARIOUS PHASES OF CLINICAL DEVELOPMENT

20

  • COST-SAVING GENERIC PHARMACEUTICALS

  • PREVENTIVE VACCINES

  • DIAGNOSTIC TOOLS

  • CONSUMER HEALTH CARE PRODUCTS

  • LOW COST QUALITY MEDICINES

  • FAST GROWING SEGMENTS OF HEALTHCARE.

  • CORE COMPETENCIES IN SCIENTIFIC DISCOVERY AND DEVELOPMENT TO CONTINUE DRIVING.

  • INNOVATION.

  • GROWTH

TRAINING UNDERGONE

Learning at Novartis

“If we can transform ordinary people into extraordinary people to achieve extraordinary things, then we really have fulfilled the leadership challenge.”

Dr. Daniel Vasella, Chairman of Novartis

Our executive programs are developed in close cooperation with the world’s leading business minds professors and learning consultants from world-class institutions such as Harvard Business School, Stanford, IMD, Tuck, Babson and others.

Proven learning methods encourage participants to discuss their own real business issues, exchange ideas and solve problems. Custom-designed corporate programs bring together executives from all over the world to build the necessary skills, informal networks, insight and teamwork essential for success.

The programs take place in a learning environment that stimulates collaboration and sharing of ideas and builds strong personal and professional bonds among Novartis leaders.

Novartis Pharmaceuticals conducted seminars to educate staff about their benefits packages

21

Success stories

Rankings and awards

Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our corporate responsibility activities.

SCRIP awards 2012

21 Success stories Rankings and awards Novartis is honored to receive numerous awards for progress in

Novartis awarded two of the prestigious SCRIP Awards for excellence in innovation and R&D

21 Success stories Rankings and awards Novartis is honored to receive numerous awards for progress in

Newsweek 2012 Green Rankings

Novartis is the greenest healthcare company worldwide

22

22 2012/13 Dow Jones Sustainability World Index Novartis is a member of the 2012/13 Dow Jones

2012/13 Dow Jones Sustainability World Index

Novartis is a member of the 2012/13 Dow Jones Sustainability World Index, which recognizes the leading sustainability-driven companies worldwide.

MedAdNews

22 2012/13 Dow Jones Sustainability World Index Novartis is a member of the 2012/13 Dow Jones

Novartis

named

“Most

consecutive year.

Admired Pharmaceutical Company
Admired
Pharmaceutical
Company

2012”

for

the

4th

Science’s 2012 Top Employer

Novartis ranked no. 11 on Science’s Top 20 Employers list.

22 2012/13 Dow Jones Sustainability World Index Novartis is a member of the 2012/13 Dow Jones

Eurobrand’s Global Top 100 Brand Corporations

Novartis brand ranks no. 39 globally and no. 2 in Switzerland.

23

23 2012 Working Mother’s 100 Best Companies Novartis Pharma US named one of the best employers

2012 Working Mother’s 100 Best Companies

Novartis Pharma US named one of the best employers for working mothers.

23 2012 Working Mother’s 100 Best Companies Novartis Pharma US named one of the best employers

Universum’s World’s Most Attractive Employers

Novartis named one of the top 50 most attractive employers worldwide for engineering students by Universum.

23 2012 Working Mother’s 100 Best Companies Novartis Pharma US named one of the best employers

Swiss Graduate Barometer 2012 Handelszeitung

Novartis ranked most popular employer in healthcare by Swiss students in Swiss Graduate Barometer.

23 2012 Working Mother’s 100 Best Companies Novartis Pharma US named one of the best employers

24

European Graduate Barometer 2012 Frankfurter AllgemeineZeitung

Novartis enters the list of the 50 preferred employers among European Engineering/IT students.

24 European Graduate Barometer 2012 – Frankfurter AllgemeineZeitung Novartis enters the list of the 50 preferred

Transparency in corporate reporting: Assessing the world’s largest companies

Novartis named the most transparent large healthcare company by Transparency International

24 European Graduate Barometer 2012 – Frankfurter AllgemeineZeitung Novartis enters the list of the 50 preferred

2012 Ethical Corporation Awards

Novartis wins Ethical Corporation Award for Best Corporate/NGO Partnership for SMS for Life

24 European Graduate Barometer 2012 – Frankfurter AllgemeineZeitung Novartis enters the list of the 50 preferred

World’s Most Respected Companies 2012 by Barron’s

Novartis ranks again as the most respected healthcare company in “The World’s Most Respected Companies” by US business magazine Barron’s

25

25 Top Employer in Switzerland 2012 by Universum /Bilanz Novartis again ranked No. 1 employer in

Top Employer in Switzerland 2012 by Universum /Bilanz

Novartis again ranked No. 1 employer in Switzerland for students in Natural Science by Swiss business magazine Bilanz and Universum

25 Top Employer in Switzerland 2012 by Universum /Bilanz Novartis again ranked No. 1 employer in

Computerworld’s 21st Century Achievement Awards

SMS for Life has been honored with the 21st Century Achievement Award in the Innovation IT category of the 2012 Computerworld Honors Program. This award recognizes organizations that promote and advance the public welfare, benefit society and change the world for the better through a visionary application of IT.

25 Top Employer in Switzerland 2012 by Universum /Bilanz Novartis again ranked No. 1 employer in

Bilanz magazine Sustainability Ranking 2012

Novartis again ranked as a top sustainability performer

25 Top Employer in Switzerland 2012 by Universum /Bilanz Novartis again ranked No. 1 employer in

The Scientist’s Best Places to Work: Industry 2012

26

26 Pharmaceutical Executive “PharmExec 50” For the second time, Novartis is No. 2 in PharmExec's 2012

Pharmaceutical Executive “PharmExec 50”

For the second time, Novartis is No. 2 in PharmExec's 2012 ranking of the top 50 pharma companies based on Rx sales.

26 Pharmaceutical Executive “PharmExec 50” For the second time, Novartis is No. 2 in PharmExec's 2012

FT Bowen Craggs Index 2012

Bowen Craggs ranks Novartis No.8 in its 6 th annual index of corporate web effectiveness, making it the second healthcare company on the list.

26 Pharmaceutical Executive “PharmExec 50” For the second time, Novartis is No. 2 in PharmExec's 2012

Interbrand’s “Most Valuable Swiss Brands 2012”

Novartis named #3 Most Valuable Swiss Brand 2012 by Interbrand/Bilanz with a brand value of CHF 6.8 billion.

26 Pharmaceutical Executive “PharmExec 50” For the second time, Novartis is No. 2 in PharmExec's 2012

Brand-Finance’s Top 500 most valuable global brand 2012

Novartis ranked as one of the "Global 500 most valuable brands" and one of the top brands in the pharmaceutical/healthcare sector.

27

27 Novartis CEO Joseph Jimenez receives “CEO in Action” award Novartis CEO Joseph Jimenez receives "CEO

Novartis CEO Joseph Jimenez receives “CEO in Action” award

Novartis CEO Joseph Jimenez receives "CEO in Action" award for commitment and engagement in Novartis Diversity & Inclusion initiatives.

27 Novartis CEO Joseph Jimenez receives “CEO in Action” award Novartis CEO Joseph Jimenez receives "CEO

Fortune’s World’s Most Admired Companies 2012

Novartis again ranked top pharmaceutical company in Fortune's World's Most Admired Companies 2012

27 Novartis CEO Joseph Jimenez receives “CEO in Action” award Novartis CEO Joseph Jimenez receives "CEO

SAM Sustainability Yearbook 2012

Novartis awarded Gold Class Medal in SAM's 2012 Sustainability Yearbook.

ONE MORE STORY ….

ALCON EYE CARE Transforming lives through better vision

Since its inception, Alcon has focused on developing innovative eye treatments. Alcon offers a broad range of products to treat many eye diseases and conditions and is organized into three business franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care

28

FAILURE / THREATS IN PAKISTAN AND INTERNATIONALY

WEAKNESSES

WEAKNESSES

&

  • Only one formulation is available

  • No formulation for children

THREATS

  • Mostly under dosage is recommended

  • Lack of resources to top attractive opportunities

EXISTING THREATS

POTENTIAL THREATS

  • High share of voice of customers

  • Intro of new molecules Compliance is

  • Increased penetration of low cost generics in institutions

low

  • Rapid growth of below the line & direct to consumer advertising

ENTRY/EXIT INTO THE INDUSTRY

  • Increasingly high acceptance of valproates

  • Increase in number of neuro science

  • Competitive products

  • Consumers have been offered more choices

THREATS

  • Patent expiry for diovan/co-diovan

WEAKNESSES

franchise In 2011/12 longer term risk of patent expiry for Gilvac ( in 2015)

  • Failure of galvus to position NOVARTIS in DIABATES market

  • Considerable risk of late stage pipeline attrition ,heightened by these products accounting for significant proportion of 2013 forecast sales

29

Conclusion

It is concluded from the report that,

The external business environment analysis revealed that Novartis benefits from a growing global pharmaceuticals market. Growth is caused by new emerging markets ,aging global population and more diseases caused by changing lifestyles. On the other hand, governments put increasingly pressure on pharmaceutical companies to lower prices and increase drug availability. In terms of sales and market share, Novartis is currently one of the top five largest pharmaceuticals producers in the world with a market share of about 5%.From the internal analysis it can be concluded that Novartis has an attractive, diversified and rejuvenated product portfolio with many recently launched new products that are still in the introduction and growth phase, making Novartis less reliant on Diovan. It is noteworthy that Novartis is the only major pharmaceuticals producer that also has the capability to market generic drugs. This might become more important in the future as governments around the world try to lower health care.This might become more important in the future as governments around the world try to lower health care costs. The analysis also showed that Novartis has considerable competitive advantage in key industry success factors such as R&D, competent employees, financial strength, marketing and sales and organizational efficiency. This is vital for Novartis to maintain its strategy of developing new and effective drugs and while focusing on growth areas in the pharmaceuticals industry , competent employees, financial strength, marketing and sales and organizational efficiency

30

RECOMMENDATIONS TO OVERCOME THREATS

  • Formulation should be introduced for children & young adults

  • Promotional strategies to create awareness & increase mind share

  • Promote kols to the number of patients

  • Optimise the loyalty base of tegral users

  • Switch epival users to tegral

  • Low dosage range extension should be introduced

  • In the regions other than Karachi ,Lahore &Peshawar distribution should be made more extensive to increase availability

  • More agents should be contacted

  • Management should strategies their aims to retain their sales force through benefit planning & incentives.

To overcome weaknesses

  • Conduct seminars &workshops to train GPS global positioning system about epilepsy &the usage of tegral

  • Treatment gap should be reduced by awareness programs in rural areas

  • Cost-plus pricing should be practice for new molecules exposure & regulations for safety should be enhanced

  • Local firms desirous of export , buy lacking necessary export structure.

To achieve the opportunities

  • Capitalize on strong CNS frenchise

  • Patient evaluation programs

  • Keep (key experts evaluation programs pain full diabetic NEUROPATHIES for 30 physician

  • BOC 2 programs for 30 doctors each for PDN

  • Epilepsy project

  • CME (continuing medical education) programs for family physicians

  • Only 28 epilepsy camps are organised so far

  • Neuroscience summit : patent evaluation programs for major brands of NEUROSCIENCE .

31

  • Total35 top kols (autoimmune diseases) from NEUROLOGY & PSYCHATRY.

BIBLIOGRAPHY

MOST

  • DR.M.QASIM AWAN

PHARMA-D.R.PH

EXTENSIVE

RESOURCE

FOR

EX.HOSPITAL PHARMACIST SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL LAHORE.

  • Master Thesis

MSc in Finance & International Business A Valuation of Novartis including a Real Option

Analysis Based on a Drug R&D Project Academic Advisor: Peter Løchte Jørgensen (PhD)

Århus School of Business September 2010

  • March 2011 pdf report by heif financial officer of Novartis

By JONATHAN SYMONDS

  • Report about Novartis published by MIRZA ABBASS GLOSSARY

Generic drugs

A drug which is produced & distributed with out patent protection

Epival

Valproate semi sodium

CNS Central nervous system

PDN Potential indifferent indications

32

Neuropathies Any pathology of the peripheral nerves Pipeline industry Discovery &new developments Epilepsy Disorder of nervous system FDA Food & drug administration Ophthalmology Is the branch of medicine that deals with the physiology & diseases of the eye. Immunities The ability to resist a particular toxin by the action of specific antibodies.